224 related articles for article (PubMed ID: 15055565)
21. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
22. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis.
Katelaris CH; Ciprandi G; Missotten L; Turner FD; Bertin D; Berdeaux G;
Clin Ther; 2002 Oct; 24(10):1561-75. PubMed ID: 12462286
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
Butrus S; Greiner JV; Discepola M; Finegold I
Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
[TBL] [Abstract][Full Text] [Related]
27. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
29. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.
Rosenwasser LJ; Mahr T; Abelson MB; Gomes PJ; Kennedy K
Allergy Asthma Proc; 2008; 29(6):644-53. PubMed ID: 19063816
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
Sanchis-Merino ME; Montero JA; Ruiz-Moreno JM; Rodriguez AE; Pastor S
Exp Eye Res; 2008 May; 86(5):791-7. PubMed ID: 18378229
[TBL] [Abstract][Full Text] [Related]
31. A review of olopatadine for the treatment of ocular allergy.
Abelson MB
Expert Opin Pharmacother; 2004 Sep; 5(9):1979-94. PubMed ID: 15330735
[TBL] [Abstract][Full Text] [Related]
32. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
33. [A multicenter, double-masked, randomized evaluation of olopatadine 0.2% using the conjunctival allergen challenge model in Japanese patients with allergic conjunctivitis].
Ohno S;
Nippon Ganka Gakkai Zasshi; 2012 Dec; 116(12):1123-9. PubMed ID: 23379201
[TBL] [Abstract][Full Text] [Related]
34. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
[TBL] [Abstract][Full Text] [Related]
35. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug.
Ohmori K; Hasegawa K; Tamura T; Miyake K; Matsubara M; Masaki S; Karasawa A; Urayama N; Horikoshi K; Kajita J; Hasegawa M; Taniguchi K; Komada T; Kawamoto Y
Arzneimittelforschung; 2004; 54(12):809-29. PubMed ID: 15646365
[TBL] [Abstract][Full Text] [Related]
36. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
37. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
[TBL] [Abstract][Full Text] [Related]
38. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
39. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears.
Abelson MB; Pratt S; Mussoline JE; Townsend D
Clin Ther; 2003 Jul; 25(7):2070-84. PubMed ID: 12946551
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
Mah FS; O'Brien T; Kim T; Torkildsen G
Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]